Suppr超能文献

多发性骨髓瘤的生存模式:一项基于瑞典1973年至2003年确诊患者的人群研究。

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

作者信息

Kristinsson Sigurdur Yngvi, Landgren Ola, Dickman Paul W, Derolf Asa Rangert, Björkholm Magnus

机构信息

Division of Hematology, Department of Medicine, Karolinska Karolinska University Hospital and Institutet, Stockholm, Sweden.

出版信息

J Clin Oncol. 2007 May 20;25(15):1993-9. doi: 10.1200/JCO.2006.09.0100. Epub 2007 Apr 9.

Abstract

PURPOSE

To define patterns of survival among all multiple myeloma (MM) patients diagnosed in Sweden during a 30-year period.

PATIENTS AND METHODS

A total of 14,381 MM patients (7,643 males; 6,738 females) were diagnosed in Sweden from 1973 to 2003 (median age, 69.9 years; range 19 to 101 years). Patients were categorized into six age categories and four calendar periods (1973 to 1979, 1980 to 1986, 1987 to 1993, and 1994 to 2003). We computed relative survival ratios (RSRs) as measures of patient survival.

RESULTS

One-year survival improved (P < .001) over time in all age groups and RSRs were 0.73, 0.78, 0.80, and 0.82 for the four calendar periods; however, improvement in 5-year (P < .001) and 10-year (P < .001) RSR was restricted to patients younger than 70 years and younger than 60 years, respectively. For the first time, in analyses restricted to MM patients diagnosed at age younger than 60 years, we found a 29% (P < .001) reduced 10-year mortality in the last calendar period (1994 to 2003) compared with the preceding calendar period (1987 to 1993). Females with MM had a 3% (P = .024) lower excess mortality than males.

CONCLUSION

One-year MM survival has increased for all age groups during the last decades; 5-year and 10-year MM survival has increased in younger patients (younger than 60 to 70 years). High-dose melphalan with subsequent autologous stem-cell transplantation, thalidomide, and a continuous improvement in supportive care measures are probably the most important factors contributing to this finding. New effective agents with a more favorable toxicity profile are needed to improve survival further, particularly in the elderly.

摘要

目的

确定瑞典30年间确诊的所有多发性骨髓瘤(MM)患者的生存模式。

患者与方法

1973年至2003年期间,瑞典共确诊14381例MM患者(男性7643例;女性6738例)(中位年龄69.9岁;年龄范围19至101岁)。患者被分为六个年龄组和四个日历时间段(1973年至1979年、1980年至1986年、1987年至1993年、1994年至2003年)。我们计算相对生存比率(RSR)作为患者生存的衡量指标。

结果

所有年龄组的1年生存率随时间有所提高(P <.001),四个日历时间段的RSR分别为0.73、0.78、0.80和0.82;然而,5年(P <.001)和10年(P <.001)RSR的提高分别仅限于70岁以下和60岁以下的患者。在首次仅限于60岁以下确诊的MM患者的分析中,我们发现与前一个日历时间段(1987年至1993年)相比,最后一个日历时间段(1994年至2003年)10年死亡率降低了29%(P <.001)。MM女性的超额死亡率比男性低3%(P = 0.024)。

结论

在过去几十年中,所有年龄组的MM 1年生存率均有所提高;年轻患者(60至70岁以下)的5年和10年MM生存率有所提高。大剂量美法仑随后进行自体干细胞移植、沙利度胺以及支持治疗措施的持续改善可能是促成这一结果的最重要因素。需要新的毒性特征更有利的有效药物来进一步提高生存率,尤其是在老年患者中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验